ASCO advances, China innovation & U.S. science under threat — a BioCentury podcast 

Data from RevMed, Akeso in the spotlight in Chicago. Plus: BioCentury’s take on China competition, OMB’s grant proposal

Revolution Medicines Inc. continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the detailed data for the company’s daraxonrasib,  Akeso Inc.’s Harmoni-6 readout, as well as other results from the American Society of Clinical Oncology’s annual meeting in Chicago.

BioCentury’s analysts then argue that U.S. biotech executives and policymakers should embrace the challenges and opportunities that come with the rise of innovation in China — rather than sticking their heads in the sand. They also discuss why leaders of the U.S.’s biggest drug companies should use their influence to stop an OMB proposal that threatens the foundations of U.S. science.

Washington Editor Steve Usdin provides takeaways from his conversation with Richard Pops, chairman and CEO of Alkermes plc, on The BioCentury Show.